GB2356139A - Use of substituted (quinolin-2-yl-methoxy)phenyl-acyl-sulphonamides and cyanamides for the treatment of diseases - Google Patents

Use of substituted (quinolin-2-yl-methoxy)phenyl-acyl-sulphonamides and cyanamides for the treatment of diseases Download PDF

Info

Publication number
GB2356139A
GB2356139A GB9926985A GB9926985A GB2356139A GB 2356139 A GB2356139 A GB 2356139A GB 9926985 A GB9926985 A GB 9926985A GB 9926985 A GB9926985 A GB 9926985A GB 2356139 A GB2356139 A GB 2356139A
Authority
GB
United Kingdom
Prior art keywords
carbon atoms
chain
straight
substituted
branched alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
GB9926985A
Other versions
GB9926985D0 (en
Inventor
Bill Taylor
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer AG
Original Assignee
Bayer AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer AG filed Critical Bayer AG
Priority to GB9926985A priority Critical patent/GB2356139A/en
Publication of GB9926985D0 publication Critical patent/GB9926985D0/en
Priority to PCT/EP2000/010919 priority patent/WO2001035936A2/en
Priority to AU23543/01A priority patent/AU2354301A/en
Publication of GB2356139A publication Critical patent/GB2356139A/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Abstract

Use of (quinolin-2-yl-methoxy)phenylacyl-sulphonamides and -cyanamides of the formula (I) <EMI ID=1.1 HE=54 WI=121 LX=518 LY=1080 TI=CF> <PC>in which<BR> A, B, D, E, L, G, X, R<SP>1</SP> and R<SP>2</SP> are described in the current specification for the treatment and prevention of glomerular nephritis, lung cancer, multiple sclerosis, ocular inflammation, osteoporosis, reperfusion injury and tinnitus.

Description

2356139 Use of substituted
(quinolin-2-yl-methoxy)phenyl-acyl-sulphonamides and - cyanamides for the treatment of diseases
Field of the Invention
The invention relates to the use of known substituted (quinolin-2-ylmethoxy)phenylacyl-sulphonamides and -cyanamides for the treatment of diseases.
Background
It is known that substituted (quinolin-2-yl-methoxy)phenylacylsulphonamides and -cyanamides are useful in the treatment of inflammatory diseases (EP-A-399 291).
Summary of the Invention
It has now been found that substituted (quinolin-2-yl-methoxy)phenylacylsulphonamides and -cyanamides of the general formula (1) A L B G I D N R R 2 E 1 (1) IH'-C-N-X 11 0 in which A, B, D, E, L and G are identical or different and represent hydrogen, hydroxyl, halogen, carboxyl, nitro, trifluoromethyl, trifluoromethoxy or a group of the formula -NR3R4, in which R3 and R4 are identical or different and denote hydrogen, straight-chain or branched alkyl having up to 8 carbon atoms or aryl having 6 to 10 carbon atoms, represent straight-chain or branched alkyl, alkoxy or alkoxycarbonyl in each case having up to 12 carbon atoms, and each of which is optionally substituted by hydroxyl, halogen, nitro, cyano or a group of the formula -NR3R4, in which R3 and R4 have the abovementioned meanings, represent aryl having 6 to 10 carbon atoms, which is optionally substituted by halogen, hydroxyl, nitro, cyano, straight-chain or branched alkyl, alkoxy or alkoxycarbonyl in each case having up to 8 carbon atoms or by a group of the formula -NR3R4, in which R3 and R4 have the abovementioned meanings, RI represents cycloalkyl having 3 to 14.-carbon atoms, which is optionally substituted by straight-chain or bia'inched.,.alkyl having up to 8 carbon atoms, R2 represents hydrogen or straight-chain or branched alkyl having up to 10 carbon atoms, which is optionally substituted by hydroxyl, alkoxy having up to 8 carbon atoms, halogen or by cycloalkyl. having 3 to 8 carbon atoms or aryl having 6 to 10 carbon atoms, which in turn may be substituted by straight-chain or branched alkyl having up to 8 carbon atoms, halogen, nitro, hydroxyl or cyano, or represents cycloalkyl having 3 to 8 carbon atoms which is optionally substituted by straight-chain or branched alkyl having up to 8 carbon atoms, or x represents a group of the formula -S02-R5, in which R5 - denotes trifluoromethyl or straight-chain or branched alkyl having up to 10 carbon atoms, which is optionally substituted by hydroxyl, halogen, cyano, alkoxy or alkoxycarbonyl in each case having up to 8 carbon atoms or by aryl having 6 to 10 carbon atoms, which in turn may be substituted by halogen, nitro, cyano or straight-chain or branched alkyl or alkoxy in each case having up to 8 carbon atoms, or denotes aryl having 6 to 10 carbon atoms, which is optionally substituted by halogen, nitro, cyano, hydroxyl, straight-chain or branched alkyl, alkoxy or alkoxycarbonyl in each case having up to 8 carbon atoms, trifluoromethyl or trifluoromethoxy, or x represents cyano and their physiologically acceptable salts can be used for the treatment and prevention of glomerular nephritic, lung cancer, multiple sclerosis, ocular inflammation, osteoporosis, reperfusion injury and tinnitus.
Detailed Description of the Invention
In the context of the present invention, physiologically acceptable salts are preferred.
Physiologically acceptable salts of the substituted (quinolin-2-ylmethoxy)phenyl acyl-sulphonamides and -cyanamides may be salts of the substances according to the invention with mineral acids, carboxylic acids or sulphonic acids. Particularly preferred salts are, for example, those with hydrochloric acid, hydrobromic acid, sulphuric acid, phosphoric acid, methanesulphonic acid, ethanesulphonic acid, toluenesulphonic acid, benzenesulphonic acid, naphthalenedisulphonic acid, acetic acid, propionic acid, lactic acid, tartaric acid, citric acid, fumaric acid, maleic acid or benzoic acid.
Salts in the context of the present invention are also salts of the monovalent metals, such as alkali metals, and the ammonium salts. Sodium salts, potassium salts and ammonium salts are preferred.
The compounds according to the invention may exist in stereoisomeric forms which behave either as image and mirror image (enantiomers) or which do not behave as image and mirror image (diastereomers). The invention relates both to the antipodes and to the racernates, and also to the diastereomeric mixtures. The racernates, like the diastereomers, can be separated into the stereoisomerically homogeneous constituents in a known manner (cf. E.L. Eliel, Stereochernistry of Carbon Compounds, McGraw Hill, 1962).
Preferred compounds of the general formula (1) are those in which A, B, D, E, L and G are identical or different and represent hydrogen, hydroxyl, fluorine, chlorine, bromine, carboxyl, nitro, trifluoromethyl, trifluoromethoxy or a group of the formula -NR3R4' in which R3 and R4 are identical or different and denote hydrogen, straight-chain or branched alkyl having up to 8 carbon atoms or phenyl, represent straight-chain or branched alkyl, alkoxy or alkoxycarbonyl in each case having up to 10 carbon atoms, and each of which is optionally substituted by hydroxyl, fluorine, chlorine, bromine, nitro, cyano or a group of the formula -NR3R4, in which R3 and R4 have the abovementioned. meanings, represent phenyl which is optionally substituted by fluorine, chlorine, bromine, hydroxyl, nitro, cyano, straight-chain or branched alkyl, alkoxy or alkoxycarbonyl in each case having up to 6 carbon atoms or by a group of the formula -NR3R4, in which R3 and R4 have the abovementioned meanings, RI represents cyclopropyl, cyclobutyl, cyclopentyl, cycloheptyl, cyclohexyl, cyclooctyl, cyclodecyl or cyclododecyl, each of which is optionally substituted by straight-chain or branched alkyl. having up to 6 carbon atoms, R2 represents hydrogen or straight-chain or branched alkyl having up to 8 carbon atoms, which is optionally substituted by hydroxyl, alkoxy having up to 6 carbon atoms, fluorine, chlorine, bromine, cyclopropyl, cyclobutyl, cyclopentyl, cycloheptyl, cyclohexyl or phenyl, which in turn may be substituted by straight-chain or branched alkyl having up to 6 carbon atoms, fluorine, chlorine or bromine or represents cyclopropyl, cyclopentyl, cyclohexyl or cycloheptyl, each of which is optionally substituted by straight-chain or branched alkyl having up to 6 carbon atoms, or represents sodium or potassium, x represents a group of the formula _S02-R5' in which R5 - denotes trifluoromethyl or straight-chain or branched alkyl having up to 8 carbon atoms, which is optionally substituted by fluorine, chlorine, bromine, alkoxycarbonyl in each case having up to 6 carbon atoms or by phenyl, which in turn may be substituted by fluorine, chlorine, bromine or by straight chain or branched alkyl or alkoxy in each case having up to 6 carbon atoms, or denotes phenyl which is optionally substituted by fluorine, chlorine, bromine, nitro, cyano, straight-chain or branched alkyl, alkoxy or alkoxycarbonyl in each case having up to 6 carbon atoms, trifluoromethyl or x represents cyano and their physiologically acceptable salts.
Particularly preferred compounds of the general formula (1) are those in which A, B, D, E, L and G are identical or different and represent hydrogen, fluorine, chlorine, bromine, nitro and trifluoromethyl, represent methyl, ethyl, propyl, isopropyl, butyl or tert.butyl, RI represents cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclooctyl, cyclodecyl or cyclododecyl, each of which is optionally substituted by methyl, ethyl, propyl or isopropyl, R2 represents hydrogen or straight-chain or branched alkyl having up to 6 carbon atoms, which is optionally substituted by cyclopropyl, cyclopentyl, cyclohexyl or cycloheptyl, - represents cyclopropyl, cyclopentyl, cyclohexyl or cycloheptyl or - represents sodium, x - represents a group of the formula _S02-R5' in which R5 - denotes trifluoromethyl, straight-chain or branched alkyl having up to 6 carbon atoms, which is optionally substituted by phenyl, which in turn is substituted by fluorine, chlorine or by straight-chain or branched alkyl having up to 4 carbon atoms, or denotes phenyl which may optionally be substituted by 20 fluorine, chlorine or straight-chain or branched alkyl having up to 4 carbon atoms, or x represents cyano and their physiologically acceptable salts.
The compounds of the general formula (I) according to the invention are known from EP-A-399 291.
"0 The acylsulphonamides and acylcyanamides of the general formula (1) according to the invention can be employed as active compounds in medicaments. The compounds act particularly as inhibitors of enzymatic reactions in the context of arachidonic acid metabolism, in particular lipoxygenase.
They are thus suitable for the treatment and prevention of glomerular nephritis, lung cancer, multiple sclerosis, ocular inflammation, osteoporosis, reperfusion injury and tinnitus.
The pharmacological activity data of the substances according to the invention are determined by the following method:
As a measure of the lipoxygenase inhibition, the release of leucotriene B4 (LTB4) from polymorphonuclear rats leucocytes (PNfNL) was determined after addition of substances and Ca ionophore by means of reverse phase HPLC according to Borgeat, P. et al., Proc. Nat. Acad. Sci., 76, 2148-2152 (1979). The in vivo activity of the compounds was detected using the mouse ear inflammation model according to Young, J.M. et al., J. of Investigative Dermatology, 82, 367-371 (1984).
In Table 1, the values obtained by this test for some compounds according to the invention are shown by way of example:
Table I
Example LO inhibition IC50 (mmol/1) 1 2.7 x 10-8 6 3.3 x 10-8 7 2.4 x 10-8 For the obtainment of systemic activity the active compounds can be administered orally or parenterally.
For parenteral administration, forms of administration to the mucous membranes (i.e.
buccal, lingual, sublingual, rectal, nasal, pulmonary, conjunctival or intravaginal) or into the interior of the body are particularly suitable. Administration can be carried out by avoiding absorption (i.e. intracardiac, intra-arterial, intravenous, intraspinal or intralumbar administration) or by including absorption (i.e. intracutaneous, sub cutaneous, percutaneous, intramuscular or intraperitoneal administration).
For the above purpose the active compounds can be administered per se or in administration forms.
Suitable administration forms for oral administration are, inter alia, normal and enteric-coated tablets, capsules, coated tablets, pills, granules, pellets, powders, solid and liquid aerosols, syrups, emulsions, suspensions and solutions. Suitable administration forms for parenteral administration are injection and infusion solutions.
The active compound can be presented in the administration forms in concentrations of from 0 - 100% by weight; preferably the concentration of the active compound should be 0.5-90% by weight, i.e. quantities which are sufficient to allow the spec ified range of dosage.
The active compounds can be converted in the known manner into the abovementioned administration forms using inert non-toxic pharmaceutically suitable auxiliaries, such as for example excipients, solvents, vehicles, emulsifiers and/or dispersants.
The following auxiliaries can be mentioned as examples: water, solid excipients such as ground natural or synthetic minerals (e.g. talcum or silicates), sugar (e.g. lactose), non-toxic organic solvents such as paraffins, vegetable oils (e.g. sesame oil), alcohols (e.g. ethanol, glycerol), glycols (e.g. polyethylene glycol), emulsifying agents, dispersants (e.g. polyvinylpyrrolidone) and lubricants (e.g. magnesium sulphate).
In the case of oral administration tablets can of course also contain additives such as sodium citrate as well as additives such as starch, gelatin and the like. Flavour enhancers or colorants can also be added to aqueous preparations for oral administration. 10 For the obtainment of effective results in the case of parenteral administration it has generally proven advantageous to administer quantities of about 0.00 1 to 10 mg/kg, preferably about 0.01 to I mg/kg of body weight. In the case of oral administration the quantity is about 0.01 to 100 mg/kg, preferably about 0.1 to 10 mg/kg of body weight. 15 It may nevertheless be necessary to use quantities other than those mentioned above, depending on the body weight concerned, the metho d of administration, the individual response to the active compound, the type of preparation and the time or interval of administration. 20 Preparation Examples Example 1 5 N-{I-[4-(Quinolin-2-yl-methoxy)phenyl]-l-cyclopentyl)-acetylmethansulphon amide Example 2 10 N-{I-[4-(Quinolin-2-yl-methoxy)-phenyl]-l-cyclopentyl}acetyl-benzylsulpho namide Example 3 15 N-{I-[4-(Quinolin-2-yl-methoxy)-phenyl]-I -cyclopentyl}acetyl-p-tolylsulphonamide Example 4 20 N-{l -[4-(Quinolin-2-yl-methoxy)-phenyl]-I -cyclopentyl)acetyl-o-tolylsulphonamide Example 5 25 N-{I-[4-(Quinolin-2-yl-methoxy)-phenyl]-l-cyclopentyl}acetyl-trifluoromet hanesulphonamide Example 6.
N-Methyl-N-1-[4-(quinolin-2-yl-methoxy)-pbenyl]-l -cyclopentyl-acetyltrifluoromethanesulphonamide 5 Example 7 N-(I-[4-(Quinolin-2-yl-methoxy)-phenyl]-l-cyclopentyl}-acetyl-cyanamide Example 8
Sodium-N-{l -[4-(quinolin-2-yl-methoxy)-phenyl]-l-cyclopentyl)-acetyltrifluoromethanesulphonamide Example 9
N-{I-[4-(Quinolin-2-yl-methoxy)-phenyl]-l-cyclohexyll-acetylmethanesulpho namide Example 10
N-(I-[4-(Quinolin-2-yl-methoxy)-phenyl]-l-cyclohexyll-acetyl-pbenzylsulph onamide Example 11
N-f 1-[4-(Quinolin-2-yl-methoxy)-phenyl]-l-cyclohexyll-acetyl-otolylsulphonam ide Example 12
N-(I-[4-(Quinolin-2-yl-methoxy)-phenyl]-l-cyclohexyl)-acetyl-cyanamide Example 13
N- {1 -[4-(Quinolin-2-yl-methoxy)-phenyl]- 1 -cycloheptyl) -acetylmethanesulphonamide Example 14
N- f 1- [4-(Quinolin-2-yl-methoxy)-phenyl]- I -cycloheptyl I -acetyltrifluoromethanesulphonamide Example 15
N-{I-[4-(Quinolin-2-yl-methoxy)-phenyl]-l-cycloheptyl)-acetyl-otolylsulph onamide Example 16
N- f I- [4-(Quinolin-2-yl-methoxy)-phenyl]- I -cyclooctyl} -acetylmethanesulphonamide Example 17
N-{I-[4-(Quinolin-2-yl-methoxy)-phenyl]-cyclodecyll-acetylmethanesulphona mide Example 18
N-f 1-[4-(Quinolin-2-yl-methoxy)-phenyl]-l-cyclodecyl)-acetylmethanesulphonamide 5 Example 19 and 20 (+)-N-1 1-[4-(Quinolin-2-yl-methoxy)-phenyl]-l-cycloheptyll-acetylmethanesulphonamide and (-)-N- ( I- [4-(Quinolin-2-yl-methoxy)-phenyl]- I -cycloheptyl) -acetyl- methane- sulphonamide

Claims (4)

  1. WHAT IS CLAIMED IS:
    I Use of a compound of the general formula (I) A F B G DN---- 2 0,,,aR' R 0 in which A, B, D, E, F and G are identical or different and represent hydrogen, hydroxyl,. halogen, carboxyl, nitro, tri fluoromethyl, trifluoromethoxy or a group of the formula - NR3R4' R3 and R4 are identical or different and denote hydrogen, straight-chain or branched alkyl having up to 8 carbon atoms or aryl having 6 to 10 carbon atoms, represent straight-chain or branched alkyl, alkoxy or alkoxy carbonyl, in each case having up to 12 carbon atoms, and each of which is unsubstituted or substituted by hydroxyl, halogen, nitro, cyano or a group of the formula -NR3R4, in which R3 and R4 have the abovementioned meanings, represent aryl having 6 to 10 carbon atoms, which is unsubstituted or substituted by halogen, hydroxyl, nitro, cyano, straight-chain or branched alkyl, alkoxy or alkoxycarbonyl in each case having up to 8 carbon atoms or by a group of the formula -NR3R4, in which R3 and R4 have the abovementioned meanings, RI represents cycloalkyl having 3 to 8 carbon atoms, which is 10 unsubstituted or substituted by straight-chain or branched alkyl having. up to 8 carbon atoms, R2 represents hydrogen or straight-chain or branched alkyl having up to 10 carbon atoms, which is unsubstituted or substituted by hydroxyl, alkoxy having up to 8 carbon atoms, halogen or by cycloalkyl having 3 to 8 carbon atoms or aryl having 6 to 10 carbon atoms, which in turn is unsubstituted or substituted by straight-chain or branched alkyl having 3 to 8 carbon 20 atoms, halogen, nitro, hydroxyl or cyano, or represents cycloalkyl having 3 to 8 carbon atoms which is unsubstituted or substituted by straight-chain or branched alkyl having up to 8 carbon atoms, or represents an alkali metal, x represents a group of the formula -S02-R5, in which denotes trifluoromethyl or straight-chain or branched alkyl R5 having up to 10 carbon atoms, which is unsubstituted or substituted by hydroxyl, halogen, cyano, alkoxy or alkoxy carbonyl. in each case having up to 8 carbon atoms or by aryl having 6 to 10 carbon atoms, which is unsubstituted or substituted by halogen, nitro, cyano or straight-chain or branched alkyl or alkoxy in each case having up to 8 carbon atoms, or denotes aryl having 6 to 10 carbon atoms, which is unsubstituted or substituted by halogen, nitro, cyano, hydroxyl, straight-chain or branched alkyl, alkoxy or alkoxycarbonyl in each case having up to 8 carbon atoms, trifluoromethyl or trifluoromethoxy, or x represents cyano and physiologically acceptable salts thereof for the manufacture of a medicament for the treatment and prevention of glomerular nephritis, lung cancer, multiple sclerosis, ocular inflammation, osteoporosis, reperfusion injury and tinnitus.
  2. 2. Use of a of the general formula (I) acording to claim I in which A, B, D, E, F and G are identifical or different and represent hydrogen, hydroxyl, fluorine, chlorine, bromine, carboxyl, nitro, trifluoromethyl, trifluoromethoxy or a group of the formula -NR3R4, in which R3 and R4 are identical or different and denote hydrogen, straight-chain or branched alkyl having up to 6 carbon atoms or phenyl, represent straight-chain or branched alkyl, alkoxy or alkoxy carbonyl, in each case having up to 10 carbon atoms, and each of which is unsubstituted or substituted by hydroxyl, fluorine, chlorine, bromine, nitro, cyano, or a group of the formula -NR3R4, in which R3 and R4 have the abovementioned meanings, represent phenyl, which is unsubstituted or substituted by fluorine, chlorine, bromine, hydroxyl, nitro, cyano, straight chain or branched alkyl, alkoxy or alkoxycarbonyl in each case having up to 6 carbon atoms or by a group of the formula -NR3R4, in which R3 and R4 have the abovementioned meanings, RI represents cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl or cycloheptyl, each of which is unsubstituted or substituted by straight chain or branched alkyl having up to 6 carbon atoms, R2 represents hydrogen or straight-chain or branched alkyl having up to 8 carbon atoms, which is unsubstituted. or substituted by hydroxyl, alkoxy having up to 6 carbon atoms, fluorine, chlorine, bromine, cyclopropyl, cyclobutyl, cyclo pentyl, cyclohexyl, cycloheptyl or phenyl, which in turn is unsub stituted or substituted by straight-chain or branched alkyl having up to 6 carbon atoms, fluorine, chlorine or bromine, or NO -1 represents cyclopropyl, cyclopentyl, cyclohexyl or cycloheptyl, each of which is unsubstituted or substituted by straight-chain or branched alkyl having up to 6 carbon atoms, or represents sodium or potassium, x represents a group of the formula -SO2-R5, in which R5 denotes trifluoromethyl or straight-chain or branched alkyl having up to 8 carbon atoms, which is unsubstituted or substituted by fluorine, chlorine, bromine, alkoxycarbonyl in each case having up to 6 carbon atoms or by phenyl, which in turn is unsubstituted or substituted by fluorine, chlorine, bromine or by straight-chain or branched alkyl or alkoxy in each case having up to 6 carbon atoms, or denotes phenyl, which is unsubstituted or substituted by fluorine, chlorine, bromine, nitro, cyano, straight-chain or branched alkyl, alkoxy or alkoxycarbonyl in each case having up to 6 carbon atoms or trifluoromethyl, or x represents cyano and physiologically acceptable salts thereof for the manufacture of a medicament for the treatment and prevention of glomerular nephritis, lung cancer, multiple sclerosis, ocular inflammation, osteoporosis, reperfusion injury and tinnitus.
  3. 3. Use of a compound of the general formula (1) according to claim I in which A, B, D, E, F and G are identical or different and represent hydrogen, fluorine, chlorine, bromine, nitro or trifluoromethyl, represent methyl, ethyl, propyl, isopropyl, butyl or tert.-butyl, RI represents cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl or cycloheptyl, each of which is unsubstituted or substituted by methyl, propyl. or isopropyl, R2 represents hydrogen or straight-chain or branched alkyl having up to 6 carbon atoms, which is unsubstituted or substituted by cyclopropyl, cyclopentyl, cyclohexyl or cycloheptyl, represents cyclopropyl, cyclopentyl, cyclohexyl or cycloheptyl, or represents sodium, x represents a group of the formula -S02-R5, in which R5 denotes trifluormethyl, straight-chain or branched alkyl having up to 6 carbon atoms, which is unsubstituted or substituted by phenyl which in turn is substituted by fluorine, chlorine or by straight-chain or branched alkyl having up to 4 carbon atoms, or denotes phenyl which is unsubstituted or substituted by fluorine, chlorine or straight-chain or branched alkyl having up to 4 carbon atoms, or x represents cyano and physiologically acceptable salts thereof for the manufacture of a medicament for the treatment and prevention of glomerular nephritic, lung cancer, multiple sclerosis, ocular inflammation, osteoporosis, reperfusion.
    injury and tinnitus.
  4. 4. Use of N-fl-[4-(Quinolin-2-yl-methoxy)phenyl]-l-cycloheptyl-acetylmeth- anesulphonamide of the formula CH-CO-NH-SO2-CH 3 for the manufacture of a medicament for the treatment and prevention of glomerular nephritis, lung cancer, multiple sclerosis, ocular inflammation, osteoporosis, reperfusion injury and tinnitus.
GB9926985A 1999-11-15 1999-11-15 Use of substituted (quinolin-2-yl-methoxy)phenyl-acyl-sulphonamides and cyanamides for the treatment of diseases Withdrawn GB2356139A (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
GB9926985A GB2356139A (en) 1999-11-15 1999-11-15 Use of substituted (quinolin-2-yl-methoxy)phenyl-acyl-sulphonamides and cyanamides for the treatment of diseases
PCT/EP2000/010919 WO2001035936A2 (en) 1999-11-15 2000-11-06 Use of substituted (quinolin-2-yl-methoxy)phenyl-acyl-sulphonamides and -cyanamides for the treatment of diseases
AU23543/01A AU2354301A (en) 1999-11-15 2000-11-06 Use of substituted (quinolin-2-yl-methoxy)phenyl-acyl-sulphonamides and -cyanamides for the treatment of diseases

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB9926985A GB2356139A (en) 1999-11-15 1999-11-15 Use of substituted (quinolin-2-yl-methoxy)phenyl-acyl-sulphonamides and cyanamides for the treatment of diseases

Publications (2)

Publication Number Publication Date
GB9926985D0 GB9926985D0 (en) 2000-01-12
GB2356139A true GB2356139A (en) 2001-05-16

Family

ID=10864542

Family Applications (1)

Application Number Title Priority Date Filing Date
GB9926985A Withdrawn GB2356139A (en) 1999-11-15 1999-11-15 Use of substituted (quinolin-2-yl-methoxy)phenyl-acyl-sulphonamides and cyanamides for the treatment of diseases

Country Status (3)

Country Link
AU (1) AU2354301A (en)
GB (1) GB2356139A (en)
WO (1) WO2001035936A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR037097A1 (en) 2001-10-05 2004-10-20 Novartis Ag ACILSULFONAMID COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND THE USE OF SUCH COMPOUNDS FOR THE PREPARATION OF A MEDICINAL PRODUCT

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5091392A (en) * 1989-05-23 1992-02-25 Bayer Aktiengesellschaft Substituted (quinolin-2-yl-methoxy)phenyl-acyl-sulphon-amides and -cyanamides, processes for their preparation and their use in medicaments
US5391747A (en) * 1989-05-23 1995-02-21 Bayer Aktiengesellschaft Substituted (quinolin-2-yl-methoxy)phenyl-acyl-sulphon-amides and -cyanamides, processes for their preparation and their use in medicaments
US5597833A (en) * 1992-08-11 1997-01-28 Bayer Aktiengesellschaft Substituted quinol-2-yl-methoxy-phenylacetic acid derivatives

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2079586T3 (en) * 1990-10-12 1996-01-16 Merck Frosst Canada Inc HYDROXIALKYLQUINOLINE ETHER ACIDS AS LEUCOTRENE ANTAGONISTS.
DE4235133A1 (en) * 1992-10-19 1994-04-21 Bayer Ag Crystalline (R) - (-) - 2-cycloheptyl-N-methylsulfonyl- [4- (2-quinolinyl-methoxy) phenyl] acetamide

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5091392A (en) * 1989-05-23 1992-02-25 Bayer Aktiengesellschaft Substituted (quinolin-2-yl-methoxy)phenyl-acyl-sulphon-amides and -cyanamides, processes for their preparation and their use in medicaments
US5391747A (en) * 1989-05-23 1995-02-21 Bayer Aktiengesellschaft Substituted (quinolin-2-yl-methoxy)phenyl-acyl-sulphon-amides and -cyanamides, processes for their preparation and their use in medicaments
US5597833A (en) * 1992-08-11 1997-01-28 Bayer Aktiengesellschaft Substituted quinol-2-yl-methoxy-phenylacetic acid derivatives

Also Published As

Publication number Publication date
GB9926985D0 (en) 2000-01-12
WO2001035936A3 (en) 2002-03-28
WO2001035936A2 (en) 2001-05-25
AU2354301A (en) 2001-05-30

Similar Documents

Publication Publication Date Title
US11730737B2 (en) Aldose reductase inhibitors and uses thereof
HU203228B (en) Process for producing new thiazole derivatives and leukotriene-antagonist pharmaceutical compositions comprising same as active ingredient
EP3757107B1 (en) 4-oxo-3,4-dihydrothieno[3,4-d]pyridazine compounds as aldose reductase inhibitors and methods of use thereof
EP3192796B1 (en) Aldose reductase inhibitors and uses thereof
JP2002507611A (en) Imidazolone appetite suppressants: II. Phenyl derivative
PT2046740E (en) Compounds having crth2 antagonist activity
WO2008066145A1 (en) Thiazole derivative and use thereof as vap-1 inhibitor
AU2020257075B2 (en) Methods and agents for treating disease
KR20170003688A (en) Heterocyclic Hydroxamic Acids as Protein Deacetylase Inhibitors and Dual Protein Deacetylase-Protein Kinase Inhibitors and Methods of Use Thereof
US6617357B2 (en) Compounds and their use as PDE inhibitors
KR20010101730A (en) 2,3,4,5-tetrahydro-1h-[1,4]benzodiazepine-3-hydroxamic acid as matrix metalloproteinase inhibitors
GB2356139A (en) Use of substituted (quinolin-2-yl-methoxy)phenyl-acyl-sulphonamides and cyanamides for the treatment of diseases
WO2015150364A1 (en) Substituted benzotriazinone butane acids and use thereof
US6326378B1 (en) Use of thiadiazolo[4,3-a]pyridine derivatives
JP2890448B2 (en) Pyrazolopyridine mevalonolactones
JPH03501972A (en) Dopamine-β-hydroxylase inhibitor
EP0831092B1 (en) Hydroquinone derivative and pharmaceutical use thereof
JP2004523493A (en) Use of pyrazolo [4,3-d] pyrimidines
HU211268A9 (en) Cycloalkylthiazole derivatives
JP2003530396A (en) Novel therapeutically useful salts of CCK inhibitors, methods for their preparation and pharmaceutical products containing them
JP2004504269A (en) Use of PDEV inhibitors
US5120744A (en) Substituted (quinolin-2-yl-methoxy)phenylthioureas
WO2001035960A1 (en) Use of substituted 4-(quinolin 2-yl-methoxy)phenyl-acetic acid derivatives for the treatment of diseases
EP0877026B1 (en) Substituted 6-r-1,3,4-thiadiazine-2-amines, the use thereof as anaesthetising, cardiovascular and hypometabolic agents, and a pharmaceutical composition containing them
WO1999045002A1 (en) Benzofuran derivatives

Legal Events

Date Code Title Description
WAP Application withdrawn, taken to be withdrawn or refused ** after publication under section 16(1)